Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.

Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M.

Diabet Med. 2008 Mar;25(3):333-40. doi: 10.1111/j.1464-5491.2007.02375.x.

PMID:
18307460
2.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
3.

Rosiglitazone: potential beneficial impact on cardiovascular disease.

Viberti GC.

Int J Clin Pract. 2003 Mar;57(2):128-34. Review.

PMID:
12661797
4.

Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.

Viberti G.

J Diabetes Complications. 2005 May-Jun;19(3):168-77. Review.

PMID:
15866064
5.

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

Doggrell SA.

Expert Opin Pharmacother. 2008 Feb;9(3):405-20. doi: 10.1517/14656566.9.3.405 . Review.

PMID:
18220491
6.

Pioglitazone plus glimepiride: a promising alternative in metabolic control.

Derosa G.

Int J Clin Pract Suppl. 2007 Jun;(153):28-36. Review.

PMID:
17594391
7.

Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.

Donnelly R.

Int J Clin Pract. 2007 Jul;61(7):1160-9. Epub 2007 May 18. Review.

PMID:
17511791
8.

The anti-atherogenic effects of thiazolidinediones.

Stojanovska L, Honisett SY, Komesaroff PA.

Curr Diabetes Rev. 2007 Feb;3(1):67-74. Review.

PMID:
18220657
9.
10.
11.

Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.

Dandona P, Aljada A.

J Diabetes Complications. 2004 Mar-Apr;18(2):91-102. Review.

PMID:
15120703
12.

Physical activity/exercise training in type 2 diabetes. The role of the Italian Diabetes and Exercise Study.

Balducci S, Zanuso S, Fernando F, Fallucca S, Fallucca F, Pugliese G; Italian Diabetes Exercise Study (IDES) Group.

Diabetes Metab Res Rev. 2009 Sep;25 Suppl 1:S29-33. doi: 10.1002/dmrr.985. Review.

PMID:
19662617
13.

The effect of thiazolidinediones on adiponectin serum level: a meta-analysis.

Riera-Guardia N, Rothenbacher D.

Diabetes Obes Metab. 2008 May;10(5):367-75. Epub 2007 Jul 21. Review.

PMID:
17645557
14.

Adiponectin in health and disease.

Oh DK, Ciaraldi T, Henry RR.

Diabetes Obes Metab. 2007 May;9(3):282-9. Review.

PMID:
17391153
15.

Cardiovascular effects of the thiazolidinediones.

Qayyum R, Schulman P.

Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):88-97. Review.

PMID:
16184618
16.

[Antihyperglycaemic treatment and vascular diseases].

Svacina S.

Vnitr Lek. 2010 Apr;56(4):313-6. Review. Czech.

PMID:
20465102
17.

Adiponectin gene and cardiovascular risk in type 2 diabetic patients: a review of evidences.

Ferrarezi DA, Cheurfa N, Reis AF, Fumeron F, Velho G.

Arq Bras Endocrinol Metabol. 2007 Mar;51(2):153-9. Review.

18.

[Physiological effects of exercise training in patients with type 1 diabetes].

De Angelis K, da Pureza DY, Flores LJ, Rodrigues B, Melo KF, Schaan BD, Irigoyen MC.

Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1005-13. Review. Portuguese.

19.

Clinical thiazolidinediones as PPARgamma ligands with the potential for the prevention of cardiovascular disease in diabetes.

de Dios ST, O'Brien RC, Little PJ.

Curr Diabetes Rev. 2006 May;2(2):227-39. Review.

PMID:
18220629
20.

New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.

McGuire DK, Inzucchi SE.

Circulation. 2008 Jan 22;117(3):440-9. doi: 10.1161/CIRCULATIONAHA.107.704080. Review. No abstract available.

Supplemental Content

Support Center